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Aim. Mesenchymal stem cells (MSCs) isolated from human bone marrow (hBM) and adipose tissue (hAT) are perceived as
attractive sources of stem cells for cell therapy. The aim of this study was to compare MSCs from hBM and hAT for their
immunocytochemistry staining and resistance to in vitro apoptosis. Methods. In our study, we investigated the antiapoptotic
ability of these MSCs toward oxidative stress induced by hydrogen peroxide (H2O2) and serum deprivation. Results were assessed
by MTT and ﬂow cytometry. All experiments were repeated a minimum of three times. Results. Flow cytometry and MTT
analysis revealed that hAT-MSCs exhibited a higher resistance toward H2O2-induced apoptosis (n = 3, hBM-hAT viability
H2O2 58.43±1.24–73.02±1.44,P<0.02)andtoserum-deprivation-inducedapoptosisatdays1and4thanthehBM-MSCs(n = 3,
hAT-hBM absorbance, resp., day 1: 0.305±0.027–0.234±0.015, P = 0.029, day 4: 0.355±0.003–0.318±0.007, P = 0.001, and day
7: 0.400 ± 0.017–0.356 ± 0.008, P = 0.672). hAT-MSCs showed superior tolerance to oxidative stress triggered by 2mmol/LH2O2
and also have superior antiapoptosis capacity toward serum-free culture. Conclusion. In this study we found that hAT-MSCs are
more resistant to in vitro apoptosis.
1.Introduction
Ischaemic heart disease (IHD) is the major cause of con-
gestive heart failure and subsequent mortality in devel-
oped countries. Despite the most advanced therapeutic and
interventional treatments, such as percutaneous coronary
intervention (PCI) or coronary artery bypass graft (CABG),
thenumberofpatientssuﬀeringfromheartfailureisincreas-
ing. End-stage disease can only be treated by heart trans-
plantation when all other medical treatments have failed.
But it is hampered by a lack of suitable donor organs [1].
Cell transplantation has raised hope as a new therapeutic
modality. Cell transplantation as an adjunctive therapy to
promote myocardial function after an acute myocardial in-
farction (AMI) has been widely studied in both experimental
and clinical conditions. Results from studies have revealed
that injection of stem cells can improve myocardial function
by inducing angiogenesis and inhibiting apoptosis [2, 3].
The goal of cell transplantation is the substitution of scarred
myocardium with viable cells ultimately leading to overall
improvement of myocardial function. Two of the most wide-
ly used cell types for cardiac repair today are myoblasts and
human-bone-marrow- (hBM-) derived progenitors. Human
adipose tissue (hAT) is also perceived as attractive source of
stem cells for cell therapy. hAT-derived cells in the infarcted
heart have never been compared directly to hBM-derived
mesenchymal stem cells (MSCs) in clinical trials. Although
the in vitro properties of hAT- and hBM-derived MSCs have
been compared before [4, 5], there are no reports evaluating
antiapoptotic ability of MSCs isolated from hBM and hAT.2 The Scientiﬁc World Journal
The aim of this study was to compare MSCs from hBM and
hAT for their immunocytochemistry staining and resistance
to in vitro apoptosis.
2.MaterialsandMethods
All of the biological materials used in this study were
collected after the approval of the Ethics Committee, Kocaeli
University, and informed consent was signed by the patients
according to institutional guidelines under the approved
protocol.
2.1. Isolation and Culture of Human BM-Derived MSCs.
hBM-MSCs were isolated from bone marrow of the patients
who went under immune thrombocytopenic purpura.
Mononuclear cells were separated by centrifugation over a
Ficoll-Hypaque gradient (Sigma Chemical Co., St. Louis,
MO) and suspended in α-MEM medium (Biochrom-
FG0325) containing 15% FBS (FBS; Invitrogen/GIBCO,
Grand Island, NY, USA) and 100IU/mL penicillin-
100μg/mL streptomycin (Invitrogen/GIBCO) followed by
plating at an initial seeding density of 1 × 106 cells/cm2.A l l
of the cells isolated from ﬁve samples were plated in diﬀerent
25cm2 medium-containing culture ﬂasks. After seven days
of incubation, the media were replaced, and replacement
was then performed twice a week. In the primary cell culture
after cells reached conﬂuency of 80–90% they were treated
with 0.025% trypsin-EDTA for 3min, and the released cells
were collected by centrifugation and replated at a rate of
1:3-1:4 for subculturing. Passage 3 MSCs were used in all
experiments.
2.2. Isolation and Culture of Human AT-Derived MSCs. In
brief hATs were obtained from subcutaneous material after
uncomplicated elective caesarean deliveries from healthy
mothers. Tissue samples were washed several times with
Hanks’ balanced salt solution (HBSS) with 5% antibiotic-
antimycoticsolutionandwithoutcalciumandmagnesiumto
remove blood (Invitrogen). Tissues were minced into small
blocks and a single cell suspension of adipose tissue cells
was obtained by using enzymatic digestion and mechanical
means.
The enzymatic digestion procedure was performed as
described below.
The ﬁnely cut hATs were moved to a 50mL conical
tube (BD Biosciences) and then chemically decomposed in
α-MEM (Modiﬁed Eagle Medium, Gibco) medium sup-
plemented with 5mL of %0,075 lik collagenase type 2
(SIGMA, St. Louis, MO) at 37◦C for 60 minutes in a shaking
water bath rotating at 150rpm. At 20min intervals, the
digests were pipetted vigorously and dissociation monitored
microscopically. After approximately 60 minutes the cell
suspensions were ﬁltered using a 70μm cell strainer (Becton
Dickinson Labware, Franklin Lakes, NJ, USA) to separate
single cells from debris and undigested adipose tissue frag-
ments. Cells were seeded into 25cm2 culture ﬂask containing
α-MEM supplemented with 100U/mL penicillin, 0.1mg/mL
streptomycin, and 15% FBS. Seven days after the initiation
of culture, the medium was changed twice a week. After cells
reached 80–90% conﬂuence, they were treated with 0.025%
trypsin-EDTA for 3min. The released cells were collected,
centrifuged, and replated at rate of 1:3-1:4 for subculture.
3.FlowCytometry
To conﬁrm that MSCs maintain their phenotypic charac-
teristics after growth in culture, undiﬀerentiated SCs were
subjected to ﬂow cytometry analysis. After each passage,
stem cells were harvested and suspended in their own
culture medium at a concentration of 1 × 106 cells/mL. Flow
cytometry was performed by using a FACS Calibur (BD
Biosciences, San Diego, USA). The data were analysed with
Cell Quest software (BD Biosciences) and the forward and
side scatter proﬁle gated out debris and dead cells.
Immunophenotyping of MSCs was performed with an-
tibodies against the following human antigens: CD3, CD8,
CD10, CD11b, CD13, CD14, CD15, CD19, CD33, CD34,
CD44, CD45, CD71, CD73, CD90, CD117, CD146, CD166,
and HLA-DR. All of the antibodies were supplied by Becton
Dickinson.
4. Immunohistochemistry
To identify cellular markers, P3 cells were seeded on poly-
L-lysine-coated 8-well chamber slides (BD Biosciences),
cultured for another 1-2 days and subjected to immunocy-
tochemistry and immunoﬂuorescence staining.
4.1.ImmunoﬂuorescenceStaining. Sampleswererinsedbrief-
ly in PBS, ﬁxed in ice-cold methanol for 10min, and then
allowed to dry completely. After permeabilisation with
0.025% Triton X-100 (Merck, Darmstadt, Germany), the
cells were incubated with 1.5% normal goat or donkey
blocking serum (Santa Cruz Biotechnology) in PBS for
30min at 37◦C to suppress nonspeciﬁc binding of IgGs.
After washing three times with PBS (5min each) the cells
were incubated overnight at 4◦C with the primary antibodies
listed in Table 1. After three PBS washes, cells were incubated
with FITC and Texas-red- (Santa Cruz Biotechnology)
labelled appropriate secondary antibodies for 25min in
dark. After washing three times with PBS, the cells were
mounted with mounting medium containing DAPI (Santa
Cruz Biotechnology).
4.2. Immunoperoxidase Staining. Immunocytochemical ana-
lysis was performed using the streptavidin-peroxidase
method (UltraVision Plus Large Volume Detection System
Anti-Polyvalent, HRP immunostaining Kit, Thermo Scien-
tiﬁc, UK). To reduce nonspeciﬁc background staining due to
endogenous peroxidase, cultured cells were ﬁxed in ice-cold
methanolwith0.3%hydrogenperoxide(CarloErbaReactifs,
Val-De-Reuil Cedex Pa Des Portes, FRANCE) for 15min
and allowed to dry. After additional PBS washes, cells were
incubatedwithUltraVBlockfor5minatroomtemperature.
Then, cells were incubated overnight at 4◦C with the
primary antibodies listed in Table 1. The following day, cells
were incubated with biotinylated secondary antibodies for
15min at room temperature. Incubations were followedThe Scientiﬁc World Journal 3
Table 1: Immunocytochemical properties of hAT-MSCs and hBM-MSCs.
Antibody/marker Dilution
Cell type
hAT-MSCs hBM-MSCs
detection detection
CD 31/PECAM-1 (M-20) 1:100 ∅∅
CD 34 (C-18) 1:150 ∅∅
CD 44/HCAM (Ab-4) 1:150 + +
CD 45 (H-230) 1:150 ∅∅
CD 71 (K-20) 1:150 ∅∅
CD105/Endoglin (M-20) 1:100 + +
Vimentin (C-20) 1:100 + +
Fibronectin (EP5) 1:100 + +
by streptavidin peroxidase treatment for 15min at room
temperature and signals were detected with the AEC kit
(Zymed Laboratories, UK). The cells were counterstained
with hematoxylin (Santa Cruz Biotechnology) and examined
under a light microscope (Leica DMI 4000B, Wetzlar, Ger-
many). After induction of apoptosis (described below) cells
were stained with caspase-3.
5.ApoptosisInductionandDetection
5.1. 2mmol/L H2O2-Induced Apoptosis. At passage 3 hBM-
MSCs and hAT-MSCs (n = 3) were seeded into 6-well plate
at a density of 10 × 104/cm2 a n dc u l t u r e df o raf u r t h e r4 8h
and medium changed to apoptosis inducing medium that
contains 2mmol/L H2O2 MEM ve 10% FBS. After 60min,
cellswerewashedwithPBSandapoptoticcellpercentagewas
detected by ﬂow cytometry with Annexin-V-FITC Apoptosis
Detection Kit (BD Pharmingen). The data were analyzed
with the Cell Quest software (BD Biosciences).
5.2. Serum-Deprivation-Induced Apoptosis. Analysis of MTT
was made using MTT Cell Growth Kit (Chemicon). hAT-
and hBM-MSCs at passage 3 were seeded at 12.500 cells per
well in 6-well plates and were incubated in 5% CO2,3 7 ◦C
for 1, 4, and 7 days. Then culture medium was replaced.
Wells were washed twice with phosphate-buﬀer saline (PBS).
In the growth curve experiment, 10μLM T T( 0 . 5 m g / m L )
was added and the culture was incubated for 4h. 100μL
isopropanol/HCl was added to culture medium. Absorbance
at 570nm was measured by a UV-visible spectrophotometer
microplate reader (VersaMax, Molecular Device, USA). For
each group, experiments were repeated three times, and
measurements were done in triplicates.
5.3. Statistical Analysis. All experiments were performed as
triplicates. Data are reported as means ± SD. All statisti-
cal analyses were performed using SPSS 10.0 (SPSS Inc.,
Chicago, IL, USA). Data were analyzed using one-way
ANOVA and paired t-test. Diﬀerences between the exper-
imental and control groups were regarded as statistically
signiﬁcant when P<0.05.
6. Results
6.1. Isolation and Culture of hBM-MSCs and hAT-MSCs.
MSCs attached to the culture ﬂasks sparsely and displayed
a ﬁbroblast-like, spindle-shaped morphology during the
initial days of incubation. After 3-4 days of incubation,
proliferation started and the cells gradually grew into small
colonies named colony-forming units (CFU). By the time
t h e ya r e6t o8d a y so fa g e ,c o l o n i e sw i t hd i ﬀerent sizes
increasedinnumber.Asgrowthcontinued,adjacentcolonies
interconnected with each other and a monolayer conﬂuence
was obtained after 12 to 16 days of incubation (Figures 1(a)
and 1(d)). In later passages, MSCs exhibited large, ﬂattened
or ﬁbroblast-like morphology (Figures 1(b), 1(c), 1(e),a n d
1(f)).
6.2. Flow Cytometry Identiﬁcation of hAT- and hBM-MSCs.
Deﬁned markers exist that especially and uniquely identify
MSCs. We utilised some markers to deﬁne our cultured
cells. Our data indicated that hAT-MSCs and hBM-MSCs
expressed CD13, CD44, CD73, CD90, CD146, and CD166,
but not CD3, CD8, CD10, CD11b, CD14, CD15, CD19,
CD33, CD34, CD45, CD71, CD117, and HLA-DR. These
ﬁndings are consistent with their undiﬀerentiated state, and,
similar to hBM-MSCs, they possessed immunophenotypic
MSCs characteristics as shown in Figures 2(a) and 2(b).
6.3. Immunocytochemical Properties of hAT- and hBM-MSCs.
Typical immunoreactivity proﬁles of hAT- and hBM-MSCs
are speciﬁed in Table 1. Under the standard culture condi-
tions, these cells expressed MSC markers such as CD105/
endoglin, CD44, CD146, vimentin, and ﬁbronectin and their
morphological characteristics remained unchanged (Figures
2 and 3). As summarized in Table 1, hAT- and hBM-MSCs
did not express surface markers like CD31, CD34, and CD45
(hematopoietic markers) or CD71 (transferrin receptor).
6.4. Antiapoptosis Ability of MSCs. Apoptosis triggered by
2mmol/L H2O2. After 60min of 2mmol/L H2O2 induction,
obvious morphology changes in the hAT- and hBM-MSCs
were observed by light microscopy (data not shown). Cell
apoptosis was measured by Annexin V-FITC, which binds4 The Scientiﬁc World Journal
(a) (b) (c)
(d) (e) (f)
Figure 1: Representative ﬁelds showing hBM- and hAT-MSCs morphologies for diﬀerent passages. (a-b) hBM-MSCs in culture. During
the onset of culture P0: 12th day (a), P2: 1st day (b), and P3: 7th day (c). MSCs attached to the culture ﬂasks sparsely and displayed a
ﬁbroblast-like, spindle-shaped morphology during the initial days of incubation. After 5–7 days of incubation, proliferation started and
the cells gradually grew into small colonies (a). After the next passages, most of these MSCs exhibited large, ﬂattened morphology (b, c).
(c-d) Representative ﬁelds showing hAT-MSCs morphologies for diﬀerent passages ((c) P0: 12th day, (d) P2: 4th day, and (e) P3: 6th day).
hAT-MSCs were observed to appear morphologically very similar to hBM-MSCs.
to phosphatidylserine residues that are redistributed from
the inner to the outer leaﬂet of the cell membrane as an
early event in apoptosis. After loss of membrane integrity,
PI can enter the cell and intercalate into DNA [6]. Figures
4(a) and 4(b) show the percentages of Annexin V-PI-stained
cells of hAT- and hBM-MSCs. The average percentages of
Annexin V+-PI+ (late apoptotic cells) were the highest in
hBM-MSCs (20.77% ± 1.87), and the percentage in hBM-
MSCs was the lowest (10.29% ± 0.81). As shown in Figures
4(a) and 4(b),H 2O2 induced a signiﬁcant decrease in the
viability rates of hAT-MSCs compared with hBM-MSCs
(73.02 ± 1.44–58.43 ± 1.24, resp., P = 0.002). Moreover,
there was a statistical signiﬁcance between hAT-MSCs and
hBM-MSCs as well as the rate of Annexin V+/PI− (early
apoptotic cells) and Annexin V−/PI+ (necrotic cells) (data
not shown). Therefore, this suggested that hAT-MSCs had a
superior tolerance to H2O2-induced cytotoxicity.
During ischemia, multiple changes contribute to cellular
death. Among these are deprivation of nutrients, growth
and survival factors, and oxygen. Serum deprivation is
known to induce apoptosis in various cell types including
stem cells [7]. To determine whether MSCs can tolerate
ischemia, the cells were exposed to serum deprivation (SD).
After serum withdrawal for 1, 4, and 7 days, hAT- and
hBM-MSCs were analyzed by MTT. Active mitochondrial
dehydrogenase of living cells can cleave MTT to produce
formazan, the amount of which directly correlates with the
number of metabolically active cells. hBM-MSCs showed
inferior tolerance to serum-free culture than hAT-MSCs. In
serum-free culture, proliferation index of hAT-MSCs that
has shown viable cell ratio was higher than that of hBM-
MSCs at the 1st and 4th days (n = 3, hAT- and hBM-MSCs
mean absorbance values, resp., for the 1st day: 0.305 ± 0.027,
0.236 ± 0.015, P = 0.042, for the 4th day: 0.355 ± 0.003,
0.318 ± 0.007, P = 0.011). Interestingly, there was not a
statistically signiﬁcant diﬀerence between the survivability of
MSCs at the 7th day (n = 3, hAT- and hBM-MSCs mean
absorbance values, resp., the 7th day: 0.400 ± 0.017, 0.356 ±
0.008, P = 0.081) (Figure 4(c)).
Caspase-3 is the most extensively studied apoptotic pro-
tein. Caspase-3 is synthesized as an inactive proenzyme that
is processed in cells undergoing apoptosis by self-proteolysis
and/orcleavagebyanotherupstreamprotease.Thecaspase-3
immunohistochemistry technique is a simple, easy, and reli-
able method for the early identiﬁcation and quantiﬁcation
of apoptotic cells in histological sections [8]. hBM-MSCs
showed the most sensitive reaction to oxidative stress in that
most of cells showed intense caspase-3 immunoreactivity
(data not shown). In contrast to hBM-MSCs, hAT-MSCs
showed superior tolerance to oxidative stress with the least
morphological change.
7. Discussion
MSCs are showing great potential for the treatment of
cardiovascular diseases, in particular ischaemic heart diseaseThe Scientiﬁc World Journal 5
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(b) hBM-MSCs
Figure 2: Representative ﬂow cytometry analysis of cell-surface markers in hAT-MSCs (a) and hBM-MSCs (b) at passage 3. Cells were
labeled with antibodies against hematopoietic antigens (CD3, CD8, CD10, CD14, CD15, CD33, CD34, CD45, CD71, CD117, and HLA-DR)
and MSC markers (CD13, CD44, CD73, CD90, CD146, and CD166) or immunoglobulin isotype antibodies and analyzed by ﬂow cytometry
as above. Green line, control immunoglobulin. A representative example of more than two experiments.6 The Scientiﬁc World Journal
CD44
CD105
Vimentin
Fibronectin
hAT-MSCs hBM-MSCs
Figure 3: Immunophenotype of cultured hAT- and hBM-MSCs.
Studies based on immunoperoxidase and immunoﬂuorescence
reactivities were performed on third passage cultures of hMSCs.
Representative staining patterns are shown for CD 44, CD105,
vimentin, and ﬁbronectin. Nuclei were counterstained with haema-
toxylin and were labeled with DAPI (blue). Scale bars = 50μm.
and heart failure. Results from animal studies and initial
human trials are encouraging [9–17]. MSCs can be found
in bone marrow, muscle, skin, dental pulp, cord blood,
amnioticﬂuid,andadiposetissue.MSCsarecharacterizedby
the potential to diﬀerentiate into muscle, ﬁbroblasts, bone,
and adipose tissue [18]. Two of the most widely used cell
types for cardiac repair today are myoblasts and BM-derived
progenitors. Adipose tissue (AT) is also perceived as attrac-
tive source of stem cells for cell therapy. To our knowledge
this study is the ﬁrst study comparing antiapoptotic ability
of hBM-derived MSCs and hAT for the purpose of setting up
aninvitroevaluationtesttohelpchoosingabettercellsource
for clinical trials.
The major ﬁndings are as follows: (1) hAT-MSCs are
a promising source due to their high proliferation ability.
(2) Flow cytometry and MTT analysis showed that hAT-
MSCs possess higher resistance toward H2O2-a n ds e r u m -
deprivation-induced apoptosis than hBM-MSCs.
Kern et al. compared morphology, the success rate of iso-
latingMSCs,colonyfrequency,expansionpotential,multiple
diﬀerentiation capacity, and immune phenotype of human
MSCs isolated from umbilical cord blood (UCB), BM, and
AT.ThisstudyrevealedthatthesuccessrateofisolatingMSCs
washigherinATandBMthaninUCB.UnlikeAT,whichhad
the highest colony-forming frequency, the colony-forming
frequency was the lowest in UCB. UCB-MSCs showed no
adipogenic diﬀerentiation capacity, in contrast to BM- and
AT-MSCs.AuthorsconcludedthatUCBandATareattractive
alternatives to BM in isolating MSCs [19].
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Figure 4: (a-b) Apoptosis was quantiﬁed by FACS analysis after
staining with Annexin V and PI after incubation with H2O2 for
60min. Cell apoptosis was measured by Annexin V-FITC, which
binds to phosphatidylserine residues that are redistributed from the
inner to the outer leaﬂet of the cell membrane as an early event
in apoptosis. After loss of membrane integrity, PI can enter the
cell and intercalate into DNA (I: necrotic cell; II: late apoptotic
cell; III: viable cell; IV: early apoptotic cell.) (c) Serum deprivation
induced a reduction in viability determined by MTT. The results
were presented as the ratio of apoptosis induced by 2mmol/L H2O2
or serum deprivation (mean ± SD, n = 3e a c h ,∗P<0.05, ∗∗P<
0.01).The Scientiﬁc World Journal 7
Peng et al. compared immunophenotypic characteriza-
tion, proliferation capacity, diﬀerentiation ability, expression
of angiogenic cytokines, and antiapoptotic ability of MSCs
of adult Sprague Dawley rats derived from adipose tissue,
bone marrow, and cartilage [7]. They investigated the an-
tiapoptotic ability of these MSCs toward oxidative stress
induced by H2O2 and serum deprivation. In this study,
based on the growth curve, cell cycle, and telomerase activity
analyses, MSCs derived from AT-MSCs possess the highest
proliferation potential, followed by MSCs derived from bone
marrow and cartilage. In terms of multilineage diﬀerentia-
tion, MSCs from all three sources have displayed osteogenic,
adipogenic,andchondrogenicdiﬀerentiationpotential.Flow
cytometry and MTT analysis have showed that cartilage-
MSCs possess the highest resistance toward H2O2-induced
apoptosis, while AT-MSCs have exhibited high tolerance
toserum-deprivation-inducedapoptosis. Authorsconcluded
that adipose tissue and cartilage are attractive alternatives to
bone marrow as sources for isolating MSCs [7].
To our knowledge there is only a single in vivo study
comparing fate and function of adipose stromal cells (ASCs)
in the infarcted heart directly to BM-derived MSCs. ASCs
and MSCs were isolated from transgenic FVB mice. Unfor-
tunately, the authors concluded that ASCs and MSCs did not
tolerate well in the cardiac environment, resulting in acute
donor cell death and a subsequent loss of cardiac function
similar to control groups [20]. hAT-derived MSCs have not
yet been compared directly to hBM-derived MSCs in clinical
studies.
The results of this study suggest that hAT may represent
an ideal source of autologous stem cells for stem cell treat-
ment. However, the process of bone marrow harvesting can
be painful and quantity of cells that can be harvested from
the patient is limited. Liposuction may be a good choice for
adipose tissue harvesting. hAT-derived MSCs largely express
the same surface markers as BM-MSC and have shown to
preserve cardiac function after infarction [21].
8. Conclusion
The ability to resist stress and apoptosis is an important
phenomenon for survival. This is especially important in
stem cell studies during which stem cells are being injected
to a damaged area for recovery purposes. If a stem cell
is more prone to apoptosis, the change of survival during
clinical practice would be less. Therefore, stem cells selected
for clinical studies should be checked for their survival rate
under stres conditions. In this study we found that hAT-
MSCs are more resistant to in vitro apoptosis.
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